Spinal and bulbar muscular atrophy is a neuromuscular disorder caused by a toxic polyglutamine (polyQ) expansion in the androgen receptor (AR). An isoform of the AR (AR-A) results from translation driven by an AUG(-II) downstream to the canonical AUG-I of AR. AR-A isoform lacks part of the N-terminal domain, including the polyQ tract. Redirecting the translation start site to the AUG-II might represent a strategy to avoid the expression of the toxic ARpolyQ, while preserving partial AR function of the shorter AR-A isoform. Strategies to switch the translation to AR-A isoform include the use of antisense oligonucleotides (ASO) to induce a steric blockage at the AUG-I encoding AR-B. To screen the ASO ability to switch AR-B to AR-A translation, we generated a reporter SH-SY5Y cell line (pScreen) expressing GFP or HiBit in frame with AUG-I or AUG-II, respectively. Ten ASOs were tested on pScreen cells, followed by HiBiT assay and GFP detection through western blot. The HiBiT assay showed that one ASO (#6) increased HiBiT-related luminescence normalised to cell viability, suggesting the induction of translation starting from the AUG-II. Instead, when we evaluated the reporter for AUG-I translation, ASO #6 also decreased GFP protein levels. In summary, there is evidence that the expression of AR isoforms can be modulated; however, the mechanisms underlying this regulation require further validation.

Strategies to promote the expression of the androgen receptor AR-A isoform lacking the polyglutamine tract in spinal and bulbar muscular atrophy / B. Tedesco, M. Chierichetti, P. Pramaggiore, V. Ferrari, L. Cornaggia, M. Cozzi, A.A.M. Mohamed, V. Marchesi, M. Piccolella, V. Crippa, P. Rusmini, M. Galbiati, C. Rinaldi, R.M. Cristofani, A. Poletti. ((Intervento presentato al convegno RNA-based innovative therapies for neurological disorders tenutosi a Napoli nel 2025.

Strategies to promote the expression of the androgen receptor AR-A isoform lacking the polyglutamine tract in spinal and bulbar muscular atrophy

B. Tedesco
Primo
;
M. Chierichetti;P. Pramaggiore;V. Ferrari;L. Cornaggia;M. Cozzi;A.A.M. Mohamed;V. Marchesi;M. Piccolella;V. Crippa;P. Rusmini;M. Galbiati;R.M. Cristofani;A. Poletti
Ultimo
2025

Abstract

Spinal and bulbar muscular atrophy is a neuromuscular disorder caused by a toxic polyglutamine (polyQ) expansion in the androgen receptor (AR). An isoform of the AR (AR-A) results from translation driven by an AUG(-II) downstream to the canonical AUG-I of AR. AR-A isoform lacks part of the N-terminal domain, including the polyQ tract. Redirecting the translation start site to the AUG-II might represent a strategy to avoid the expression of the toxic ARpolyQ, while preserving partial AR function of the shorter AR-A isoform. Strategies to switch the translation to AR-A isoform include the use of antisense oligonucleotides (ASO) to induce a steric blockage at the AUG-I encoding AR-B. To screen the ASO ability to switch AR-B to AR-A translation, we generated a reporter SH-SY5Y cell line (pScreen) expressing GFP or HiBit in frame with AUG-I or AUG-II, respectively. Ten ASOs were tested on pScreen cells, followed by HiBiT assay and GFP detection through western blot. The HiBiT assay showed that one ASO (#6) increased HiBiT-related luminescence normalised to cell viability, suggesting the induction of translation starting from the AUG-II. Instead, when we evaluated the reporter for AUG-I translation, ASO #6 also decreased GFP protein levels. In summary, there is evidence that the expression of AR isoforms can be modulated; however, the mechanisms underlying this regulation require further validation.
6-ott-2025
Settore BIOS-10/A - Biologia cellulare e applicata
Strategies to promote the expression of the androgen receptor AR-A isoform lacking the polyglutamine tract in spinal and bulbar muscular atrophy / B. Tedesco, M. Chierichetti, P. Pramaggiore, V. Ferrari, L. Cornaggia, M. Cozzi, A.A.M. Mohamed, V. Marchesi, M. Piccolella, V. Crippa, P. Rusmini, M. Galbiati, C. Rinaldi, R.M. Cristofani, A. Poletti. ((Intervento presentato al convegno RNA-based innovative therapies for neurological disorders tenutosi a Napoli nel 2025.
Conference Object
File in questo prodotto:
File Dimensione Formato  
Abstract TEDESCO_PNRR Oct2025.pdf

accesso aperto

Descrizione: Abstract
Tipologia: Publisher's version/PDF
Licenza: Creative commons
Dimensione 379.16 kB
Formato Adobe PDF
379.16 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1193440
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact